April 19, 2017: Immunogen’s stock popped 13% today on an upgrade from Leerink Partners. Leerink Partners raised Immunogen to an Outperform rating, from Market Perform, and set a price target of $8. Leerink Partners is upgrading Immunogen based on their higher level of conviction on lead asset mirvetuximab soravtansine providing an attractive risk/reward in context (Read More….)
April 18, 2017: Hearing vague takeover rumors circulating about Gilead Sciences. The rumor is that activist firm Jana Partners is taking a large position in order to push for a takeover. Could not find a credible source of the rumor.
April 7, 2017: The FDA approves new indications for Gilead Sciences’ Harvoni and Sovaldi in (Read More….)
April 18, 2017: Hearing vague takeover rumors circulating about Sarepta Therapeutics. The rumor is that Alexion could be interested in acquiring the company at around $55 per share. Could not find the source of the rumors.
February 14, 2017: Sarepta Therapeutic’s stock has formed a candle over candle reversal after Feuerstein said, “Sarepta Therapeutics is (Read More….)
April 16, 2017: Sell Catalyst Pharmaceuticals for a 47% gain in 60 days and congratulations if you made money on the trade.
January 4, 2017: The popular SeekingAlpha blogger Hawkinvest, with over 5,000 followers, posted a positive article on Catalyst Pharmaceuticals today that got the stock moving higher. Hawkinvest writes…
Biotech and healthcare stocks underperformed (Read More….)
March 29, 2017: Halozyme Therapeutics announced that an Oncologic Drug Advisory Committee of the U.S. Food and Drug Administration voted 11 to 0 that the benefit/risk of rituximab/hyaluronidase for subcutaneous (under the skin) injection was favorable for patients in the proposed indications of follicular lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukemia. The FDA (Read More….)
March 28, 2017: CRISPR Therapeutics reported that the European Patent Office (EPO) has announced its intention to grant a patent broadly covering CRISPR’s in-licensed gene editing technology. The claims are directed to the CRISPR/Cas9 single-guide gene editing system for uses in both non-cellular and cellular settings, including in cells from vertebrate animals such as human (Read More….)
March 4, 2017: Sell Global Blood Therapeutics for a monster 91% win in 41 days! Congratulations if you were able to make money on the trade.
January 4, 2017: JPMorgan Chase initiates coverage of biotechnology firm Global Blood Therapeutics with an Overweight rating and a price target of $25. JPMorgan thinks GBT440 is a (Read More….)
February 23, 2017: Wells Fargo initiated coverage of JUNO on February 22, 2017 with an Outperform rating. Then, one day later on February 23, 2017, Wells Fargo downgraded JUNO to market perform! Was this a rotational dump at $24 and we just provided Wells Fargo the liquidity they needed? I don’t know but my trust (Read More….)
February 17, 2017: Celgene announced that its phase III SUNBEAM trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (ARR), compared to weekly interferon (IFN) ß-1a (Avonex).
SUNBEAM evaluated two (Read More….)
February 14, 2017: Sell Cynosure for a huge 36.5% win in 28 days. Cynosure will be acquired by Hologic for $66 per share. Congratulations if you were able to make money on this trade.
February 7, 2017: Cynosure reports Q4 EPS of $0.44 versus the $0.41 estimate. Revenue also beat coming in at $122 million (Read More….)
January 29, 2017: Astellas Pharma and Ironwood Pharmaceuticals announced today top-line results indicating that the Phase III clinical trial of linaclotide conducted in Japan in adults with chronic constipation (CC) met its primary endpoint.
Linaclotide is approved in Japan as the first prescription treatment for adults with irritable bowel syndrome with constipation (IBS-C). Linaclotide is (Read More….)
January 23, 2017: TheStreet.com’s Feuerstein says Celgene should considering buying Biogen. Source: http://realmoney.thestreet.com/articles/01/23/2017/5-reasons-celgene-should-buy-biogen
January 13, 2017: Biogen presented new data from the Phase 3 ENDEAR study of SPINRAZA (nusinersen), which demonstrated a statistically significant reduction in the risk of death or permanent ventilation in SPINRAZA-treated infants with spinal muscular atrophy (SMA) compared to untreated infants. (Read More….)
January 19, 2017: AbbVie announced that the U.S. Food and Drug Administration (FDA) approved IMBRUVICA (ibrutinib) for the treatment of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. This indication is approved under accelerated approval based on overall response rate (ORR), and (Read More….)
January 9, 2017: Biotechnology firm PTC Therapeutics’ stock broke above the 200 day MA today as it received notification from the European Commission (EC) of its adoption of a positive decision granting annual renewal of the conditional marketing authorization for Translarna (ataluren). The positive decision is based on the recent renewal recommendation by the Committee (Read More….)
January 8, 2017: Institutional traders are accumulating biotechnology firm Anavex Life Sciences according to recent 13F filings. The institutional traders who bought the most shares of Anavex Life Sciences are:
BlackRock Fund Advisors = bought 843,994 shares according to 11-11-2016 filing BlackRock Institutional Trust = bought 284,540 shares according to 11-11-2016 filing State Street Corp (Read More….)
January 7, 2017: Biotechnology firm CTI BioPharma announced on January 4, 2017 that the full clinical hold (February 2016) implemented by the U.S. Food and Drug Administration (FDA) on all clinical trials conducted under the Investigational New Drug (IND) application for pacritinib has now been removed. The Company’s complete response submission included, among other items, (Read More….)
December 29, 2016: OvaScience moving higher after popular biotechnology blogger makes positive comments on Twitter. @BioBreakthrough tweets: “Long 100,000 shares of $OVAS. Stock could double in early January as tax loss selling abates. ~ $4/share in cash, multiple 2017 catalysts.”
Long 100,000 shares of $OVAS. Stock could double in early January as (Read More….)
December 28, 2016: Tonix Pharmaceuticals is forming a wide J Hook pattern after having the FDA granted their PTSD drug TNX-102 a Breakthrough Therapy designation.
December 19, 2016: Tonix Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) had granted Breakthrough Therapy designation to TNX-102 SL for the treatment of posttraumatic stress disorder (Read More….)
December 27, 2016: The Ensign Group acquired the underlying real estate of fifteen assisted living operations located throughout Wisconsin. An Ensign subsidiary has been operating each facility since August 2015 under a lease with a purchase option.
The CEO said, “With our ownership of this real estate, we are excited about deepening our commitment to (Read More….)
Overnight Analyst Actions:
REGN Outperform Credit Suisse First Boston TECK Outperform Macquarie
TECK Buy MKM Partners
AMGN Neutral Credit Suisse First Boston
Overnight Headlines By Ticker:
AMGN Amgen Inc
12/20 08:21 Credit Suisse Cuts AMGN to Neutral from Outperform, price target: $180
12/19 (Read More….)
December 20, 2016: CytoSorbents Corp announces the launch and initial sales of its new CytoSorbCardio-Pulmonary Bypass Procedure Pack for cardiac surgery. This new product provides all of the necessary components, including the CytoSorb cartridge, to rapidly and seamlessly integrate CytoSorb into the majority of heart-lung machines used in open heart surgery today. CytoSorb has been (Read More….)
December 14, 2016: Agenus is a high-risk biotechnology moonshot play on the clinical trial of anti-OX40 checkpoint antibody INCAGN1949 in patients with solid tumors. On November 30, 2016, Agenus announced that the first patient has been dosed in a Phase 1/2 clinical trial of the anti-OX40 agonist antibody INCAGN1949. The trial is being conducted by, (Read More….)